Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Plus Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Plus Therapeutics, Inc.’s stock price such as:

• Plus Therapeutics, Inc.’s current stock price and volume
• Why Plus Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for PSTV from analysts
• PSTV’s stock price momentum as measured by its relative strength

About Plus Therapeutics, Inc. (PSTV)

Before we jump into Plus Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

Want to learn more about Plus Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Plus Therapeutics, Inc..

Plus Therapeutics, Inc.’s Stock Price as of Market Close

As of May 13, 2026, 9:42 AM, CST, Plus Therapeutics, Inc.’s stock price was $5.800.

Plus Therapeutics, Inc. is down 0.85% from its previous closing price of $5.850.

During the last market session, Plus Therapeutics, Inc.’s stock traded between $5.800 and $5.880. Currently, there are approximately 5.51 million shares outstanding for Plus Therapeutics, Inc..

Plus Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Plus Therapeutics, Inc. Stock Price History

Plus Therapeutics, Inc.’s (PSTV) price is currently down 5.54% so far this month.

During the month of May, Plus Therapeutics, Inc.’s stock price has reached a high of $6.650 and a low of $5.740.

Over the last year, Plus Therapeutics, Inc. has hit prices as high as $23.425 and as low as $2.900. Year to date, Plus Therapeutics, Inc.’s stock is down 54.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Plus Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 12, 2026, there were 0 analysts who downgraded Plus Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Plus Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Plus Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Plus Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Plus Therapeutics, Inc. (PSTV) by visiting AAII Stock Evaluator.

Relative Price Strength of Plus Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 12, 2026, Plus Therapeutics, Inc. has a weighted four-quarter relative price strength of -23.00%, which translates to a Momentum Score of 9 and is considered to be Very Weak.

Want to learn more about how Plus Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Plus Therapeutics, Inc. Stock Price: Bottom Line

As of May 13, 2026, Plus Therapeutics, Inc.’s stock price is $5.800, which is down 0.85% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Plus Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.